Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia

被引：8
|
作者：
Kreuzer, Karl-Anton [1 ]
Furman, Richard R. [2 ]
Stilgenbauer, Stephan [3 ]
Dubowy, Ronald L. [4 ]
Kim, Yeonhee [4 ]
Munugalavadla, Veerendra [4 ]
Lilienweiss, Esther [1 ]
Reinhardt, Hans Christian [1 ]
Pettitt, Andrew R. [5 ]
Hallek, Michael [1 ]
机构：
[1] Univ Cologne, Dept Intern Med 1, Cologne, Germany
[2] Weill Cornell Med Coll, New York, NY USA
[3] Ulm Univ Med Ctr, Dept Intern Med 3, Ulm, Germany
[4] Gilead Sci Inc, Foster City, CA USA
[5] Univ Liverpool, Liverpool, Merseyside, England
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.192.192
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
192
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study
    Seymour, John F.
    Kipps, Thomas J.
    Eichhorst, Barbara F.
    Hillmen, Peter
    D'Rozario, James M.
    Assouline, Sarit
    Owen, Carolyn Jane
    Gerecitano, John
    Robak, Tadeusz
    De la Serna, Javier
    Jaeger, Ulrich
    Cartron, Guillaume
    Montillo, Marco
    Humerickhouse, Rod
    Punnoose, Elizabeth
    Li, Yan
    Boyer, Michelle
    Humphrey, Kathryn
    Mobasher, Mehrdad
    Kater, Arnon P.
    BLOOD, 2017, 130
  • [22] ASCEND Phase 3 study of acalabrutinib versus investigator's choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    de la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abe
    Avery, E. J.
    Lee, Jae Hoon
    Liang, Wei
    Patel, Priti
    Quah, Cheng
    Jurczak, Wojciech
    LEUKEMIA & LYMPHOMA, 2020, 61 : 235 - 237
  • [23] Ascend Phase 3 Study of Acalabrutinib vs Investigator's Choice of Rituximab Plus Idelalisib (IDR) or Bendamustine (BR) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Hebart, Holger
    Ghia, Paolo
    Jurczak, Wojciech
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kryachok, Irina
    Illes, Arpad
    De la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric
    Patel, Priti
    Quah, Cheng
    Liang, Wei
    Lee, Jae Hoon
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 128 - 129
  • [24] Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia
    Robak, Tadeusz
    Smolewski, Piotr
    Cebula, Barbara
    Grzybowska-Izydorczyk, Olga
    Blonski, Jerzy Z.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (02) : 107 - 113
  • [25] Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia-Results From Pre-Planned Interim Analysis of the Randomized Phase 3 MURANO Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 12 - 14
  • [26] Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)
    Spacek, Martin
    Smolej, Lukas
    Simkovic, Martin
    Nekvindova, Lucie
    Kristkova, Zlatuse
    Brychtova, Yvona
    Panovska, Anna
    Maslejova, Stanislava
    Bezdekova, Lucie
    Ecsiova, Dominika
    Vodarek, Pavel
    Zuchnicka, Jana
    Mihalyova, Jana
    Urbanova, Renata
    Turcsanyi, Peter
    Lysak, Daniel
    Novak, Jan
    Brejcha, Martin
    Likarova, Tereza
    Vodicka, Prokop
    Baranova, Jana
    Trneny, Marek
    Doubek, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (01) : 40 - 47
  • [27] The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab
    Panovska, Anna
    Smolej, Lukas
    Lysak, Daniel
    Brychtova, Yvona
    Simkovic, Martin
    Motyckova, Monika
    Vodarek, Pavel
    Lindtnerova, Michaela
    Trbusek, Martin
    Malcikova, Jitka
    Pospisilova, Sarka
    Mayer, Jiri
    Doubek, Michael
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (06) : 479 - 485
  • [28] Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study
    Huang, Xiaojun
    Qiu, Lugui
    Jin, Jie
    Zhou, Daobin
    Chen, Xiequn
    Hou, Ming
    Hu, Jianda
    Hu, Yu
    Ke, Xiaoyan
    Li, Junmin
    Liang, Yingmin
    Liu, Ting
    Lv, Yue
    Ren, Hanyun
    Sun, Aining
    Wang, Jianmin
    Zhao, Chunting
    Salman, Mariya
    Sun, Steven
    Howes, Angela
    Wang, Jingzhao
    Wu, Peng
    Li, Jianyong
    CANCER MEDICINE, 2018, 7 (04): : 1043 - 1055
  • [29] Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG)
    Pula, Bartosz
    Budziszewska, Bozena Katarzyna
    Rybka, Justyna
    Gil, Lidia
    Subocz, Edyta
    Dlugosz-Danecka, Monika
    Zawirska, Daria
    Waszczuk-Gajda, Anna
    Iskierka-Jazdzewska, Elzbieta
    Kopacz, Agnieszka
    Szymczyk, Agnieszka
    Czyz, Jaroslaw
    Lech-Maranda, Ewa
    Warzocha, Krzysztof
    Jamroziak, Krzysztof
    ANTICANCER RESEARCH, 2018, 38 (05) : 3025 - 3030
  • [30] Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial
    Ghia, Paolo
    Coutre, Steven E.
    Cheson, Bruce D.
    Barrientos, Jacqueline C.
    Hillmen, Peter
    Pettitt, Andrew R.
    Zelenetz, Andrew D.
    Shreay, Sanatan
    Hallek, Michael
    Furman, Richard R.
    HAEMATOLOGICA, 2020, 105 (10) : E519 - E522
12345